BEUTH, J and KO, HL and TUNGGAL, L and BUSS, G and JELJASZEWICZ, J and STEUER, MK and PULVERER, G (1994) DOSE-DEPENDENT IMMUNOACTIVE EFFECTS OF MISTLETOE LECTIN-1. ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 44-2 (11). pp. 1255-1258. ISSN 0004-4172,
Full text not available from this repository.Abstract
Galactoside-specific mistletoe lectin-1 (ML-1) was isolated by affinity chromatography from proprietary mistletoe extract and checked in BALB/c mice for its immunoactive potency. To investigated the optimal immuno-modulating dosage, ML-1 (0.5, 1.0, 2.5, 5.0 ng/kg body weight, b.w.) was subcutaneously administered for three subsequent days followed by another injection of 1 ng ML-1/kg b.w. induced optimal immunomodulation, since thymocyte proliferation, maturation and emigration were significantly enhanced in this murine model as compared to non-treated control mice. Furtheron, counts of peripheral blood lymphocytes and monocytes as well as expression of relevant activation markers on these cells revealed significant increases after ML-1 (1 ng/kg b.w.) administration. However, increase of cell counts and activity of peritoneal macrophages were less pronounced but still statistically significant for this ML-1 concentration. Determination of immune responses after low dose ML-1 treatment (0.5 ng/kg b.w.) presented relevant (partly statistically significant) increases, too. However, high dose ML-1 treatment (2.5, 5.0 ng/kg/ b.w.) did not enhance (but suppress) relevant immune functions. For future clinical/therapeutical treatment strategies, ML-1 dosages ranging from 0.5-1.0 ng/kg b.w. may be supposed to be optimal.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GALACTOSIDE-SPECIFIC LECTIN; CANCER-PATIENTS; EXTRACT; CELLS; EURIXOR(R); IMMUNOMODULATORS; MISTLETOE LECTIN-1, IN VIVO STUDIES, PHARMACOLOGY |
| Depositing User: | Dr. Gernot Deinzer |
| Last Modified: | 19 Oct 2022 08:39 |
| URI: | https://pred.uni-regensburg.de/id/eprint/52987 |
Actions (login required)
 |
View Item |
